
On November 27, 2024, China’s National Medical Products Administration (“NMPA”) issued the Draft Measures for Medical Representative Administration (“Draft Measures”) for public comment. While the Draft Measures retain certain provisions from the 2020 version (“2020 Measures”)—such as prohibitions against medical representatives handling accounts receivables and processing purchase and sales notes, collecting individual HCP prescription volumes,